Application of LC/MS and related techniques to high-throughput drug discovery

Espada, Alfonso; Molina-Martin, Manuel; Dage, Jeffrey L.; Kuo, Ming‐Shang

doi:10.1016/j.drudis.2008.03.005

Cited by 35 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In such a context, radiation technology seems to be an attractive tool [18][19][20][21]. The drug with medical effects has to behave through human body, and has to be absorbed and metabolized suitably in the local cell.…”

Section: Paradigm Change In Critical Path Based On Radiation Technologymentioning

confidence: 99%

Bibliometric study of radiation application on microdose useful for new drug development

et al. 2009

View full text Add to dashboard Cite

In spite of the sharp increase in both private and government R&D fund, the number of newly approved medicines for market had decreased since the 1990s. This is attributed to a large extent to the bottleneck in the critical path arising from the great disparity between animal model in pre-clinical trial and human model in clinical trial. This bottleneck may be expected to be gotten rid of by change in paradigm of drug development based on microdosing, which is enabled by radiation-related imaging technology. However, this is impossible without being accompanied by interdisciplinary joint researches, in which clinical investigators belonging to medical schools or hospitals play the most decisive role. In this article, authors verify based on bibliometrics that Japan has not employed the opportunity for revitalizing drug research activities because Japanese researchers' attitude toward radiation technology may not be so positive in comparison with the US, and because the role which clinical investigators play in the phase of pre-clinical trial is smaller in Japan than in the US.

show abstract

Section: Paradigm Change In Critical Path Based On Radiation Technologymentioning

confidence: 99%

Bibliometric study of radiation application on microdose useful for new drug development

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The number of compounds in the lead optimization stages of the discovery process is lower compared to the HTL phase, but the information required for each compound is higher. For this reason, not only the purity but also the amount of purified compound is important since a larger quantity is required for the studies being performed at this stage [6,7]. This is reflected in the increasing importance of having an efficient chromatographic procedure to purify compounds of pharmacological interest [8,9].…”

Section: Introductionmentioning

confidence: 98%

Orthogonal analytical screening for liquid chromatography–mass spectrometry method development and preparative scale-up

Font

Fontana

Galcerán

et al. 2011

Journal of Chromatography A

View full text Add to dashboard Cite

“…In this case, the area percentage obtained by UV is used for the quantitative analysis and the MS spectrum obtained is used for the qualitative analysis (17). In addition, due to the robustness of LC-MS, this approach has been adopted as a user friendly open access service (18). • In the external standard approach, the % of RS is calculated using a standard curve.…”

Section: Introductionmentioning

confidence: 99%

Standardization of Analytical Methodology and Procedures for Purity Assessment of Small Molecules in Drug Discovery

Marín

Sharman

Burgess

et al. 2014

ACS Symposium Series

Self Cite

View full text Add to dashboard Cite

Application of LC/MS and related techniques to high-throughput drug discovery

Cited by 35 publications

References 44 publications

Bibliometric study of radiation application on microdose useful for new drug development

Bibliometric study of radiation application on microdose useful for new drug development

Orthogonal analytical screening for liquid chromatography–mass spectrometry method development and preparative scale-up

Standardization of Analytical Methodology and Procedures for Purity Assessment of Small Molecules in Drug Discovery

Contact Info

Product

Resources

About